Meluadrine

Meluadrine

SCHEMBL120043

CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 5/20 0.65
HIF1A Q16665 4/20 0.65
ADRB1 P08588 3/20 0.65
CYP2D6 P10635 2/20 0.65
NFKB1 P19838 2/20 0.65
BLM P54132 2/20 0.63
LMNA P02545 4/20 0.53
TSHR P16473 3/20 0.53
CYP3A4 P08684 2/20 0.53
CASP7 P55210 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP2C9 P11712 1/20 0.53
HTR1A P08908 1/20 0.51
SLC6A2 P23975 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRK1 P41145 1/20 0.51
SLC6A3 Q01959 1/20 0.51
KDM4E B2RXH2 2/20 0.50
CASP1 P29466 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meluadrine SCHEMBL250026 1.00 ADRB2 (0.65) ADRB2HIF1AADRB1CYP2D6NFKB1
Meluadrine SCHEMBL29508537 1.00 ADRB2 (0.65) ADRB2HIF1AADRB1CYP2D6NFKB1
Meluadrine SCHEMBL7317575 0.93 ADRB2 (0.57) ADRB2HIF1AADRB1CYP2D6NFKB1
Meluadrine SCHEMBL123344 0.91 ADRB2 (0.55) ADRB2HIF1AADRB1CYP2D6NFKB1
Meluadrine SCHEMBL1650082 0.91 ADRB2 (0.55) ADRB2HIF1AADRB1CYP2D6NFKB1
Meluadrine SCHEMBL30591457 0.91 ADRB2 (0.55) ADRB2HIF1AADRB1CYP2D6NFKB1
SCHEMBL7309792 0.88 ADRB2 (0.65) ADRB2HIF1AADRB1CYP2D6NFKB1
SCHEMBL4627723 0.87 ADRB1 (0.49) ADRB2HIF1AADRB1CYP2D6NFKB1
Meluadrine SCHEMBL5421707 0.85 ADRB2 (0.59) ADRB2HIF1AADRB1CYP2D6NFKB1
Mabuterol SCHEMBL21623862 0.82 ADRB2 (0.59) ADRB2HIF1AADRB1CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126138-B1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS INVOX BELGIUM NV (BE) 2024-10-16 EP claimed
EP-4126138-A1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS Softhale NV (BE) 2023-02-08 EP claimed
CN-115485000-A Aerosol delivery of at least two liquid compositions 索芙特海尔公司 2022-12-16 CN claimed
WO-2019178267-A2 INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2019-09-19 WO claimed
US-10377779-B2 Carbonate prodrugs and methods of using the same ACORDA THERAPEUTICS, INC. (US) 2019-08-13 US claimed
US-20190125699-A1 TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN CIPHER PHARMACEUTICALS INC. (CA) 2019-05-02 US claimed
US-20180200234-A1 COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS ALMIRALL, S.A. (ES) 2018-07-19 US claimed
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. 2018-03-29 US claimed
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 US claimed
WO-2005014044-A1 MEDICAMENTS FOR INHALATION COMPRISING BETAMIMETICS AND AN ANTICHOLINERGIC BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-02-17 WO claimed
WO-2005013992-A1 MEDICAMENTS FOR INHALATION COMPRISING BETAMIMETICS AND AN ANTICHOLINERGIC AGENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-02-17 WO claimed
US-20050026948-A1 Medicaments for inhalation comprising an anticholinergic and a betamimetic BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-02-03 US claimed
US-6624181-B1 Synergistic combination ALTANA PHARMA AG (DE) 2003-09-23 US claimed
US-6569903-B2 Comprises beta-adrenergic receptor agonist such as clenbuterol; improves tear secretion; reduced side effects on the heart ROHTO PHARMACEUTICAL CO., LTD. (JP) 2003-05-27 US claimed
EP-0842658-B1 PHOTOSTABLE AQUEOUS SOLUTION CONTAINING BENZYL ALCOHOL DERIVATIVES HOKURIKU PHARMACEUTICAL (JP) 2003-05-21 EP claimed
US-20030008805-A1 Ophthalmic compositions ROHTO PHARMACEUTICAL CO., LTD. (JP) 2003-01-09 US claimed
EP-1153614-A1 OPHTHALMIC COMPOSITIONS ROHTO PHARMACEUTICAL CO., LTD. (JP) 2001-11-14 EP claimed
US-6162833-A Photostable aqueous solution comprising benzyl alcohol derivatives HOKURIKU SEIYAKU CO., LTD. (JP) 2000-12-19 US claimed
US-5952387-A AN AQUEOUS SOLUTION COMPRISING AN OPTICAL ACTIVE ALPHA-((TERT-BUTYLAMINO)METHYL)-2-CHLORO-4-HYDROXYBENZYL ALCOHOL; USE AS A UTERINE RELAXING AGENT, BLADDER RELAXING AGENT; THERAPEUTIC TREATMENT OF PREMATURE LABOR HOKURIKU SEIYAKU CO., LTD. (JP) 1999-09-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026948-A1 Medicaments for inhalation comprising an anticholinergic and a betamimetic CHRM1, CHRND, CHRM3 ADRB2 5/4885HIF1A 2247/4885ADRB1 4/4885
US-20180200234-A1 COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS ADRB2, ADRB3, CHRM3 ADRB2 1/4885HIF1A 3593/4885ADRB1 5/4885
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA ADRB2 3813/4885HIF1A 2396/4885ADRB1 3375/4885
US-10377779-B2 Carbonate prodrugs and methods of using the same CA6, CA7, CA4 ADRB2 4334/4885HIF1A 413/4885ADRB1 4090/4885
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 ADRB2 4334/4885HIF1A 413/4885ADRB1 4090/4885
US-20190125699-A1 TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN ADRB2, ADRB1, ADRA2A ADRB2 1/4885HIF1A 2127/4885ADRB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.